MissionIR Articles
-
Using AI-Powered Models and Drug-Response Data, Predictive Oncology (NASDAQ: POAI) Holds Strong Position in Burgeoning Precision Oncology Industry
Precision oncology leverages the profile of genetic mutations in patients for the purpose of delivering precision drug-based cancer therapy Precision oncology industry forecast to be worth 99.72 billion by 2027 according to recent report POAI…
-
Predictive Oncology (NASDAQ: POAI) Releases Third-Quarter 2020 Business Update, Financial Report
Financial numbers show revenues stay level, gross margins up and operations expenses down. Company continues focus on primary mission of applying artificial intelligence to precision medicine, drug discovery. POAI subsidiaries all showing progress, growth in…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Issues Shareholder Letter Regarding Special Meeting
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today sent a letter to shareholders regarding its virtual special meeting of stockholders, originally scheduled for…
-
MissionIRNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Solution Shaves Time, Money to Optimize Therapeutic Formulations
Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. Through its subsidiary Soluble Biotech, the company delivers a solution that…
-
MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Reschedules Special Stockholder Meeting, Urges Stockholder Voting
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that its virtual Special Meeting of Stockholders, which was scheduled for Dec. 1, 2020, was…
-
Predictive Oncology’s (NASDAQ: POAI) Skyline Medical Sells 15 Streamway(R) Systems in Q3 2020 as COVID-era Drives Need for Sanitation Systems
Closed design of Streamway(R) System provides safety from potential hazards of drips and spills during endoscopy, radiology, cystoscopy, urology procedures The Streamway(R) System reduces costs, minimizes environmental impact of 50 million potentially disease-infected canisters disposed…
-
MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Q3 Numbers, Company Updates
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released its financial results and provided business updates for the quarter ended Sept. 30, 2020.…
-
Predictive Oncology (NASDAQ: POAI) CEO Discusses Subsidiaries’ Proprietary Tech, Innovative Media
CEO expects results that will “build the stock and raise the stock price” POAI focused on positioning TumorGenesis kits to manufacturers Helomics has largest database of its kind in the world, brings cutting-edge technology to…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Poised at Convergence of AI, Cancer Care
Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company, focuses on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. The company is set to play a key role as the integration…
-
Predictive Oncology (NASDAQ: POAI) CEO Joins NNW Podcast to Discuss Company’s Prospects; Provides Update on POAI Subsidiaries
Predictive Oncology CEO Carl Schwartz featured on NNW’s podcast to discuss the company’s prospects Schwartz elaborated on company’s various divisions, affirming that POAI had begun to see revenue trends stabilize, cash burn rates decline TumorGenesis…
-
Predictive Oncology (NASDAQ: POAI) Subsidiary’s HSC Technology Optimization Solution Offers Unparalleled Results, Benefits
POAI subsidiary Soluble Biotech’s optimization solution shaves time and cost off of traditional options offered by competition Results garnered from company’s HSC optimization are unparalleled in field Soluble Biotech lands first major contract, signifying major…
-
MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) CEO Provides Company Updates on Exclusive NNW Audio Interview
Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz was featured in a recent NetworkNewsWire (“NNW”) audio interview. During the interview, Schwartz provided updates on the company’s subsidiaries, noted recent company milestones and outlined near-term goals. POAI,…
-
Predictive Oncology Inc. (NASDAQ: POAI) Industry Leader in Growing Precision Medicine Market
Recent study reports CAGR of 9.7% in precision medicine space. Predictive Oncology focused on use of data, artificial intelligence to develop personalized cancer therapies. One of POAI’s primary projects is building multi-omic predictive models of…
-
MissionIRNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Looks to Bright Future with First Contract on the Books
Predictive Oncology (NASDAQ: POAI)’s Soluble Biotech division has finalized its first substantial contract with a pharmaceutical company since its acquisition by POAI earlier this year (https://ibn.fm/gXjd2). Soluble Biotech is a provider of stable and soluble…
-
Predictive Oncology Inc. (NASDAQ: POAI) CEO Schwartz Pens Letter to Shareholders, Elaborates on Ongoing Company Developments
Predictive Oncology’s CEO Carl Schwartz published open letter to company’s shareholders Schwartz elaborated on various developments within each of POAI’s divisions, has reiterated his optimism on company’s operations going forward CEO also revealed that company’s…
-
MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Shareholder Letter Provides Company Update, Status of Subsidiaries
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released a shareholder letter providing a review of where POAI “stands as of today.” The…
-
MissionIRNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics CIO Discusses Convergence of AI, Data and Biology on DojoLIVE!
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent article discussing the appearance of one of its executives, Helomics CIO…
-
Predictive Oncology Inc. (NASDAQ: POAI) Set to Capitalize on Increased AI Usage within Oncological Treatments
Predictive Oncology develops AI-solutions designed to assist clinicians in formulating personalized treatment plans for oncological patients Artificial Intelligence is being increasingly used to help understand and accurately predict how drug therapies can interact with specific…
-
Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Inks Major Contract; Skyline Medical Seals STREAMWAY Deal
POAI’s Soluble Biotech announces first substantial contract with pharmaceutical company since acquisition Founder calls contract “major milestone,” validation of move into new facility POAI’s Skyline Medical sells eight proprietary STREAMWAY(R) systems to Virginia-based hospital organization…
-
MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Granted License for Additional 71 Unique Ovarian Cancer Cell Lines
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that TumorGenesis, a division of the company, has received a license for an additional…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
- PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Marks Bold Entry Into the Growing Battery Storage Market with 4.99 MW BESS in Ontario
- Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial